Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2005

View Archived Issues

Phase II trial examines ADH-1 in N-cadherin expressing tumors

Recruitment begins in phase IIb study of DB-289 for malaria

Tsumura to file U.S. IND for Dai-kenchu-to

VEGF Trap studied in combination with FOLFOX4 regimen

TopoTarget signs CRADA for PXD-101

PulmoLAR designated orphan drug for PAH

FDA approval for phase IIb kidney transplant study of ISA-247

Cephalon to acquire Salmedix

FAS-20013 demonstrates killing effect against TB

NiKem Research and Hybrigenics expand USP inhibitor agreement

Compassionate use IND cleared for Davanat/5-FU

CCX-282 alleviates the severity of ileitis and colitis in experimental IBD

PCL-016 shows promise for adenovirus ocular infections

N-Acetylfarnesylcysteine: a novel class of topical NSAID

AJM-300 suppresses lymphocyte homing and ameliorates colitis in rats

Access and Hunter-Fleming form oral drug delivery collaboration

Genmab's new HuMax-CD38 program for multiple myeloma

Eye drops with FGLM-NH2 plus IGF-1 reported effective in neurotrophic keratopathy

Serenex selects Hsp90 inhibitors for advanced preclinical studies

Canadian approval sought for pivotal study of BST-CarGel

New immunomodulatory agents disclosed by Mitsubishi Pharma

Novel antiarthritic agents covered in recent patent literature

Syk kinase inhibitors for allergic disorders emerge from Rigel research

New agents for the treatment of lipoprotein disorders reported by Pfizer

GW-8510 and other substituted 3' substituted indolones offer neuroprotective potential

PARP-1 inhibition is neuroprotective in model of traumatic brain injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...